Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial (2015)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.2337/dc14-1850
- Subjects: DIABTES MELLITUS (COMPLICAÇÕES); FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO; INIBIDORES DE ENZIMAS; NEOPLASIAS (ETIOLOGIA)
- Language: Inglês
- Imprenta:
- Publisher place: Alexandria
- Date published: 2015
- Source:
- Título: Diabetes Care
- ISSN: 0149-5992
- Volume/Número/Paginação/Ano: v. 38, n. 4, p. 696-705, 2015
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
UDELL, Jacob A. et al. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, v. 38, n. 4, p. 696-705, 2015Tradução . . Disponível em: https://doi.org/10.2337/dc14-1850. Acesso em: 19 fev. 2026. -
APA
Udell, J. A., Bhatt, D. L., Braunwald, E., Cavender, M. A., Mosenzon, O., Steg, G., et al. (2015). Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, 38( 4), 696-705. doi:10.2337/dc14-1850 -
NLM
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg G, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im KA, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial [Internet]. Diabetes Care. 2015 ; 38( 4): 696-705.[citado 2026 fev. 19 ] Available from: https://doi.org/10.2337/dc14-1850 -
Vancouver
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg G, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im KA, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial [Internet]. Diabetes Care. 2015 ; 38( 4): 696-705.[citado 2026 fev. 19 ] Available from: https://doi.org/10.2337/dc14-1850 - Sex difference in patients with ischemic heart failure undergoing surgical revascularization results from the STICH trial (Surgical Treatment for Ischemic Heart Failure)
- Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial
- Patterns of Long-term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the TIMI-38 Coronary Stent Registry
- Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial
- Aneurisma Verdadeiro Gigante e Calcificado do Ventrículo Esquerdo: como Proceder?
- Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF
- Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
- Comparison between two different local hemostatic methods for dental extractions in patients on dual antiplatelet therapy: a within-person, single-blind, randomized study
- Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B
- Predictors of subclinical carotid atherosclerosis in middle-aged women
Informações sobre o DOI: 10.2337/dc14-1850 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
